Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life hemophilia treatment products
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life hemophilia treatment products
  • Published Date:

    December 06 2019

  • Source:
    Haemophilia. 26(1):e28-e30
  • Language:
    English

You May Also Like:

  1. Filetype[PDF - 41.93 KB]
    Personal Author:
    Miller, Connie H.
    Published Date:
    Sep 28 2015
    Source:
    Thromb Res. 136(6):1047-1048.
    File Type:
    Filetype[PDF - 41.93 KB]
  2. Filetype[PDF - 390.05 KB]
    Personal Author:
    Boylan, B.; Miller, C. H.;
    Published Date:
    February 20 2018
    Source:
    Haemophilia. 24(3):487-491
    Description:
    IntroductionThe use of pre-analytical heat treatment (PHT) with the Nijmegen-Bethesda assay (NBA) for inhibitors to factor VIII (FVIII) can remove/destroy infused or endogenous FVIII from patient plasma samples, allowing testing of recently infused p...
    File Type:
    Filetype[PDF - 390.05 KB]
  3. Filetype[PDF - 690.23 KB]
    Personal Author:
    Miller, C. H.
    Published Date:
    Feb 15 2018
    Source:
    Haemophilia. 24(2):186-197.
    Description:
    Inhibitors are antibodies directed against haemophilia treatment products which interfere with their function. Factor VIII (FVIII) inhibitors in haemophilia A and factor IX (FIX) inhibitors in haemophilia B are significant clinically when they requir...
    File Type:
    Filetype[PDF - 690.23 KB]
  4. Filetype[PDF - 66.27 KB]
    Personal Author:
    Sabatino, Denise E.; Pipe, Steven W.; Nugent, Diane J.; Soucie, J. Michael; Hooper, W. Craig; Hoots, W. Keith; DiMichele, Donna M.;
    Published Date:
    Jul 2019
    Source:
    Haemophilia. 25(4):575-580
    Description:
    IntroductionThe major complication of protein replacement therapy for haemophilia A is the development of anti-FVIII antibodies or inhibitors that occur in 25%−30% of persons with severe haemophilia A. Alternative therapeutics such as bypassing age...
    File Type:
    Filetype[PDF - 66.27 KB]
  5. Filetype[PDF - 595.26 KB]
    Personal Author:
    Soucie, J. Michael; Miller, Connie H.; Kelly, Fiona M.; Payne, Amanda B.; Creary, Melissa; Bockenstedt, Paula L.; Kempton, Christine L.; Manco-Johnson, Marilyn J.; Neff, Anne T.;
    Corporate Authors:
    Haemophilia Inhibitor Research Study Investigators
    Published Date:
    Nov 22 2013
    Source:
    Haemophilia. 20(2):230-237.
    Description:
    IntroductionInhibitors are a rare but serious complication of treatment of patients with haemophilia. Phase III clinical trials enroll too few patients to adequately assess new product inhibitor risk.AimThis project explores the feasibility of using ...
    File Type:
    Filetype[PDF - 595.26 KB]